新华财经北京12月13日电（可达）从相关方获悉，近日北京市卫生健康委员会向"体检10年未查 出癌症"当事人张晓玲出具了关于投诉的答复意见书（下称《意见书》）。 今年7月，律师张晓玲在社交平台实名投诉称，其在爱康国宾、北大医疗康复医院"体检10年未提 示癌症风险、确诊已是癌症晚期"，此事迅速在网络发酵。 《意见书》显示，未发现北大医疗康复医院存在误检、漏检情形；未发现北京爱康国宾西内门诊 部、北京爱康国宾中关村门诊部北京区中央实验室、北大医疗康复医院临床实验室数据及体检结果 造假情形。 《意见书》同时称，北京爱康国宾相关门诊部的肿瘤标志物（癌胚抗原，CEA）检测报告的结果 与原始测定值相同，检测结果可溯源。北大医疗康复医院实验室通过国家卫生健康委临检中心的室 间质评，检测结果可信。 《意见书》显示，CEA属于非器官特异性肿瘤相关抗原，CEA增高常见于结肠癌、直肠癌、胃癌 等多种肿瘤，CEA正常不能排除恶性肿瘤存在的可能，临床上常用于辅助诊断、疗效观察等方 面。 张晓玲此前还曾投诉积水潭医院骨肿瘤科副主任医师杨勇昆在诊疗过程中存在拖延治疗、过度医疗 以及诱导患者前往私立医院进行高价手术等问题。 根据《意见书》，经 ...

Core Insights - The article discusses the development of a "dandelion-like nanoprobe detection platform" by a research team led by Professor Zhang Yan from Qilu Normal University, aimed at addressing the challenges of sensitivity and specificity in tumor marker detection for early cancer screening [1] Group 1: Technology and Innovation - The dandelion-like nanoprobe detection platform is inspired by the seed dispersal mechanism of dandelions, providing an innovative solution for detecting trace molecules in life sciences [1] - The platform utilizes magnetic microparticles and gold nanoparticles, where the former carries specific DNA sequences to identify the "troublemaker" molecule FTO, and the latter is designed to release fluorescent signals upon detection [2][3] - The detection mechanism allows for the amplification of signals, enabling the identification of even minimal amounts of FTO, thus enhancing the sensitivity of cancer detection [3] Group 2: Clinical Applications - The ultimate goal of the research is to simplify early cancer screening to a level comparable to blood glucose testing, allowing for the detection of elevated FTO levels as potential early cancer signals [4] - The platform can be applied in various scenarios, including the detection of purified FTO, analysis of cell lysates, and tissue sample extracts, meeting diverse needs for inhibitor screening and clinical diagnosis [4] - By detecting FTO activity in blood, the platform aims to identify latent cancer cells and potentially use FTO inhibitors to restore the function of tumor suppressor genes, thereby inhibiting cancer cell proliferation [5]

Core Viewpoint - Linyi Cancer Hospital's Nuclear Medicine Department has launched new detection projects to enhance the level of tumor marker testing, providing stronger support for clinical diagnosis and treatment [1] Group 1: Cancer Statistics and Trends - Digestive tract cancers, including esophageal, gastric, and colorectal cancers, are among the most common types of malignancies in China, with three out of the top five cancers being digestive tract tumors [1] - The incidence of colorectal cancer is notably rising and becoming more prevalent among younger populations [1] Group 2: CA242 as a Tumor Marker - CA242 is a novel tumor marker derived from colorectal cancer cells, offering more specificity compared to other markers like CA19-9, CA50, and CA125, thus aiding in the early detection and prevention of digestive tract tumors [1][2] - In healthy individuals, CA242 is found in small amounts in certain cells, but its levels significantly increase in malignant tumors, particularly in pancreatic and colorectal cancers, earning it the title of "third-generation tumor marker" for these cancers [2] Group 3: High-Risk Groups for CA242 Testing - Individuals over 40 years old, those with a family history of colorectal cancer, and those with a history of other malignancies or chronic gastrointestinal issues are recommended for regular CA242 testing [4] - High-risk groups for gastric and esophageal cancers include individuals over 40, those living in high-incidence areas, and those with a family history of these cancers or pre-cancerous conditions [5] - For liver cancer, individuals with hepatitis B or C, liver cirrhosis, or a family history of liver cancer are considered high-risk [6] Group 4: PIVKA-II in Liver Cancer Screening - PIVKA-II shows superior sensitivity and specificity for hepatocellular carcinoma (HCC) screening compared to traditional markers like AFP, especially in AFP-negative patients [8] - The combination of PIVKA-II with AFP and ultrasound can enhance early detection rates of liver cancer, particularly in high-risk populations [9] Group 5: Clinical Implications - The introduction of advanced detection technologies and projects in the Nuclear Medicine Department aims to provide more accurate and comprehensive diagnostic information for early disease detection, condition assessment, and personalized treatment [9]